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Summary There is no information available on the relation between response to chemotherapy and the high-risk phenotype assessed by
uPA and/or PAI-1. The clinical situation of neoadjuvant chemotherapy provides a means of rapidly assessing the sensitivity of the primary
tumour to cytotoxic drug regimens. The goal of the study was to assess prospectively the predictive value of PAI-1 for response to first-line
chemotherapy. PAI-1 concentration was measured on hypertonic cytosolic extracts (0.4 M potassium chloride) by ELISA beforechemotherapy
on a drill biopsy sample of the tumour in 69 T2 and T3 breast cancer patients (median age 46 years). Oestrogen receptor (ER) (51% ER+),
progesterone receptor (PR) (58% PR+), S-phase (median 4.0%) and ploidy were also assessed in the majority of cases. The clinical
response to treatment was evaluated after four cycles of FAC or FEC regimen (5-fluorouracil, epidoxorubicin or doxorubicin and
cyclophosphamide) (one cycle every 4th week). PAI-1 could be assayed in 29 post-chemotherapy surgical samples. The objective response
rate (complete response plus partial response) was 59% (41 out of 69). PAI-1 expressed as gram of tissue (range 19-2370 ng g-1 tissue) was
highly correlated (r = 0.98) to PAI-1 expressed as mg protein (range 0.5-68 ng mg-1 protein). No correlation between PAI-1 level and
response could be observed, with any cut-off. The post- and pre-chemotherapy PAI-1 levels were correlated (r = 0.66). Of all biological
parameters, only high S-phase (cut-off 5%) was slightly correlated (X2 = 3.91, P= 0.05) to response. These data suggest that PAI-1 is not a
predictive marker of response to chemotherapy in breast cancer and that its level is not altered by neoadjuvant chemotherapy.
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Neoadjuvant chemotherapy provides a means of rapidly evalu-
ating the sensitivity of a primary tumour to cytotoxic drug
regimens. In breast cancer, neoadjuvant chemotherapy is used to
improve breast preservation, although no survival advantage has
yet been demonstrated (Scholl et al, 1994). It has been reported
recently that breast tumour response to primary chemotherapy
could predict local and distant control as well as survival (Scholl et
al, 1995). Predictive tests oftumour response should be developed
to more accurately select patients who may or may not benefit
from such therapy (Bonadonna et al, 1990). In this respect, the
measurement ofS-phase fraction by flow cytometry (Remvikos et
al, 1993) and detection ofmultidrug resistance (MDR) phenotype,
before or during treatment, have recently emerged as promising
predictive tests (Chevillard et al, 1996). It has been reported that
the lysosomal protease cathepsin D might be associated with
chemoresistance (Namer et al, 1991).
Urokinase plaminogen activator (uPA) is a proteolytic enzyme
involved in processes leading to tumour invasion of surrounding
tissues. Its activity during metastasis is regulated by an inhibitor,
plasminogen activator inhibitor-I (PAI-1). Previous studies have
shown that high levels of uPA and PAI-I are associated with poor
prognosis in primary breast cancers (Grondahl-Hansen et al, 1993;
Janicke et al, 1993; Bouchet et al, 1994; Duffy et al, 1996).
However, there is no information available on the relation between
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response to chemotherapy and the high-risk phenotype determined
by uPA and/or PAI-1. Recently, Foekens et al (1995) have shown
that the assay of uPA in primary breast tumours may be useful in
predicting the overall response ofmetastatic disease to tamoxifen,
patients with uPA-negative tumours exhibiting a better response.
The goal of this pilot study was to assess prospectively the
predictive value ofthe expression levels ofPAI-I before first-line
neoadjuvant chemotherapy and the response to this treatment in a
series of69 patients with primary operable breast cancer.
MATERIAL AND METHODS
Patients
Patients with operable tumours, 3 cm or more in size, with or
without clinical node involvement, with a pathological diagnosis
of invasive breast cancer established on a drill biopsy tumour
sample and aged less than 70 years were eligible for neoadjuvant
chemotherapy. Inflammatory, bilateral, locally advanced or
metastatic breast cancer were exclusion criteria for this study.
All patients received four cycles of neoadjuvant FEC or FAC
chemotherapy regimen (5-fluorouracil, epidoxorubicin or doxo-
rubicin and cyclophosphamide) before locoregional treatment.
Chemotherapy courses were administered every 4 weeks. Tumour
response was evaluated clinically and radiologically after 4
months of treatment. Responders were defined by either a
complete response (CR, disappearance of clinically palpable
disease) or partial response (PR, reduction of more than 50% of
the product of the two largest tumour diameters). Stable disease
was defined by no change in tumour size and progressive disease
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Table 1 Characteristics of the 69 patients
Age (year)
Median
Range
Menopausal status
Pre
Post
Tumour size (mm)
Median
Range
T classification
T2
T3
T4
Node status
NO
Nla
Nib
N2
Histology
Ductal
Lobular
Other
SBR
11
III
Unknown
Hormone receptors
ER+
ER-
Unknown
PR+
PR-
Unknown
Ploidy
Diploid
Aneuploid
Multiploid
Unknown
S-phase
Median
Range
Available
Unknown
2500~
46
29-70
55 (80)
14 (20)
41
30-100
45 (65)
21 (30)
3 (4)
2000
a
n .0
C,,
m 1500-
a-
1000-
500-
19 (28)
18 (26)
29 (42)
3 (4)
55 (80)
12 (17)
2 (3)
7 (10)
30 (43)
28 (41)
4 (6)
35 (51)
32 (46)
2 (3)
40 (58)
27 (39)
2 (3)
15 (22)
40 (58)
6 (9)
8 (12)
4.0a
0.7-13.8a
48 (70)
21 (30)
aS-phase median value and range are expressed as a percentage. Numbers
in parentheses are percentages.
by an increase of more than 25% in tumour size. Patients who
became eligible for conservative treatment because ofreduction of
tumour size had tumorectomy followed by radiotherapy. Non-
responders had mastectomy. Patients with poor response to
chemotherapy could be proposed for irradiation before surgery to
allow conservative treatment in case of response to radiotherapy.
All patients were submitted to fine-needle and drill biopsy
sampling at diagnosis. From October 1994 to July 1995, 69
patients with PAI-I assay on pretreatment tumour biopsy were
evaluable for clinical tumour response. Patients characteristics are
given in Table 1. Surgical samples were obtained for PAI-1 assay
from only 29 patients after chemotherapy as PAI-1 assay on this
material had not been considered in the initial phase of the study.
None ofthem had radiotherapy before surgery.
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Figure 1 Correlation between PAI-1 levels expressed in mg of protein and
in g of tissue in 58 samples of primary breast cancer
Tumour samples
At the time of diagnosis, two drill biopsies and one fine-needle
sample were obtained from all patients. Drill biopsy was performed
under local anaesthesia with a 2 mm diameterrotating drill needle.
The drill biopsy samples were 1-2 cm long with an average weight
oftumourtissue of36 mg (range 20-60 mg). One drill was fixed in
formol acetic acid andparaffin embeddedforhistological diagnosis
and histoprognostic grading. The other drill biopsy was immedi-
ately frozen in liquid nitrogen until biochemical assay of PAI-1,
oestrogen (ER) and progesterone (PR) receptors. Fine-needle
samples were obtained without aspiration with a 22-gauge needle
(Zajdela et al, 1987) and processed as previously described for
S-phase analysis by flow cytometry (Remvikos et al, 1991).
Assays
PAI-I concentration was measured by ELISA (American
Diagnostica) on hypertonic (0.4 M potassium cholride) cytosolic
extracts ofthe drill biopsy sample before chemotherapy and ofthe
surgical sample after chemotherapy, as described previously
(Romain et al, 1995). Results were expressed as ng PAI-I per
tissue weight (ng g-1 tissue) or cytosolic protein (ng mg-' protein),
as determined with Pierce protein reagent (Pierce, USA). ER and
PR were assayed on the same extract by ELISA (Abbott ER-EIA
and PR-EIA kits, Illinois, USA), according to the manufacturer's
recommendations. Receptors were considered 'positive' when
> 15 fmol mg-' protein.
DNA flow cytometry
DNA flow cytometry analysis was performed on the pretreatment
fine-needle sample of the primary tumour according to a technique
previously described (Remvikos et al, 1991). At least 10 000 cell
nuclei were analysed on a Facscan (Becton Dickinson, San Jose,
CA, USA) equipped with a doublet discrimination module. DNA
histograms with a coefficient of variation (CV) > 6% for the GIG,
peak were rejected. Tumours with a DNA index of 0.9-1.1 were
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Figure 3 Correlation between PAI-1 level before and after chemotherapy
Figure 2 PAI-1 levels in g of tissue before chemotherapy and response to
treatment. Non-responders: median 278 ng g-1 tissue, range 20-2372 ng g-1
tissue; responders: median 298 ng g-1 tissue, range 55-2151 ng g-1 tissue
classified as DNA diploid. A DNA index lower than 0.9 or higher
than 1.1 could be distinguished from a diploid marker peak, and the
tumours with such an index were classified as DNA aneuploid
(Hedley et al, 1993). The S-phase fraction (SPF) was derived using
the Cellfit software (Beckton Dickinson, San Jose, CA, USA),
including background subtraction. S-phase could be reliably derived
for 48 patients (70%), the other 21 cases displaying complex DNA
histograms (debris, multiploidy, CV greater than 6%).
Histological prognostic grade
Histological grade (SBR) was scored according to Scarff, Bloom
and Richardson (Bloom and Richardson, 1957).
Statistical analysis
The chi-square test (with Yates' correction when appropriate) was
used for comparison of 2 x 2 tables. Linear regression was used
for the correlation analysis of quantitative data (Figures 1 and 3).
The Mann-Whitney non-parametric test (Statistica) was used to
compare responders to non-responders according to PAI- 1 concen-
trations (Figure 2).
RESULTS
The objective response rate after four courses of neoadjuvant
chemotherapy was 59% (41 out of 69). There were eight patients
with complete responses, 33 with partial responses, 26 with stable
disease and two with progressive disease.
PAI-I values were available in 58 patients in ng mg-' protein
and in all 69 in ng g-' tissue. The median level ofPAI-I expressed
in ng g-' tissue was 297 (range 19-2370, mean ± s.d. = 437 ± 473).
The median level of PAI-I expressed in ng mg-' protein was 7.6
(range 0.5-68, mean 12.0 ± s.d. 12.8). Because ofthe high correla-
tion (r = 0.98) (Figure 1) between the two modes ofexpression, the
PAI-1 levels expressed in ng g- tissue were used for bioclinical
correlations, allowing a greater number of cases to be analysed.
No relation between PAI-I level and response to chemotherapy
could be observed (P = 0.66 by Mann-Whitney non-parametric
test). Medians of PAI-I values were not statistically different
between responders and non-responders (Figure 2).
The post- and pre-chemotherapy PAI-1 levels were compared in
29 patients. They were significantly correlated (r = 0.66) (Figure
3). The few variations observed were not correlated with response.
The association of different prognostic factors (age, hormonal
status, tumour size, nodal status, SBR, ER, PR, S-phase) with
clinical response was studied. Only high S-phase (cut-off5%) was
slightly correlated (%2 = 3.91, P = 0.05) with clinical response. S-
phase was 2 5% in 15 out of 28 responders (54%) vs 5 out of 20
(25%) non-responders. There was no correlation between S-phase
and PAI- I (r = 0.05).
DISCUSSION
Resistance to chemotherapy is a major clinical issue in the treat-
ment of cancer. To achieve a more effective chemotherapeutic
treatment of breast cancer patients in the future, it is essential to
define reliable indicators of response to treatment in individual
patients (Clark, 1994).
Resistance to certain drugs has been associated with an over-
expression of the multidrug resistance gene (MDR1), but the
induction ofMDRJ may be secondary to chemotherapy treatment
and does not preclude an initial response to these same drugs
(Chevillard et al, 1996). Tumours with c-erbB-2 (HER2/neu) over-
expression have also repeatedly shown not to benefit from stan-
dard adjuvant chemotherapy but could benefit from chemotherapy
dose intensification (Muss et al, 1994). Overexpression of GST2t,
frequently coamplified with members of the fibroblast growth
factor family, has equally been linked with a poor outcome despite
standard treatment (Morrow and Cowan, 1993).
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In the present study, of 69 patients receiving FAC or FEC
neoadjuvant chemotherapy for breast cancer, we failed to find any
correlation between PAI-I concentration in the tumour and
chemoresistance. In addition, in 29 patients for whom pre- and
post-chemotherapy tissue samples were available, the post-treat-
ment PAI-1 tissue concentration was similar to the pretreatment
concentration.
Fine-needle aspirates and drill biopsies ('tru-cuts' in some
instances) allow access to tumour material before treatment and
can thus be used for the assay ofbiological parameters potentially
predictive ofresponse to treatment. In the present study, PAI-I was
assayed on a drill biopsy, which yields tissue material (including
stroma), rather than on fine-needle aspirate, which provides
mainly epithelial cells, as PAI-I is thought to be largely expressed
by stromal cells (Duffy, 1996) and its prognostic value has been
established on whole tissue samples.
Whether PAI-I assay on a drill biopsy is representative of the
whole tumour may be questioned and we were not able, forethical
reasons, to test the reproducibility of the assay on different drill
biopsy samples from the same patient. Previous experience
(Magdelenat et al, 1983) with ER and PR assays supports the
hypothesis that assays on drill biopsies accurately reflect the whole
tumour status, at least for epithelial cell-associated parameters.
There are few studies in the literature that relate tumour
protease expression to response to systemic treatment. Preliminary
data suggest that high levels of uPA correlate with a lack of
response to hormonal therapy in patients with advanced breast
cancer (Foekens et al, 1995; Duffy, 1996). Cathepsin D, a serine
protease generally overexpressed in breast cancer cells under
oestrogen stimulation in ER-positive cells and constitutively over-
expressed in ER-negative cells, has been shown to be associated
with increased risk of developing metastasis (Rochefort, 1992).
Adjuvant tamoxifen was found beneficial only to node-positive,
progesterone receptor-positive breast cancers with high cathepsin
D content (Ferno et al, 1994). Namer et al (1991) suggested that
elevated cathepsin D could be associated with resistance to
chemotherapy.
The correlation between S-phase andclinical response to neoad-
juvant chemotherapy in this study is in keeping with previous ones
showing that the less breast carcinomas proliferate the more resis-
tant they are. In a previous study of 60 patients, we observed that
the pretreatment S-phase fraction was correlated with regression
of the tumour mass after the administration of neoadjuvant
chemotherapy (Remvikos et al, 1989). Cell cycle modifications
analysed by flow cytometry during neoadjuvant chemotherapy,
most frequently conceming S-phase and G2M accumulation, were
correlated with the efficacy ofcytotoxic chemotherapy in a series
of71 patients (Remvikos et al, 1993).
In conclusion, the intratumoral PAI-I level was not significantly
modified by four cycles ofneoadjuvant FAC or FEC and was not
predictive of response to these chemotherapy regimens in T2-T3
primary breast cancer.
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